SCHEDULE: Foresite Capital Boosts Stake in Eikon Therapeutics

Foresite Capital and its affiliates disclose a combined 7.7% beneficial ownership in Eikon Therapeutics, Inc. common stock.

Summary

• Foresite Capital Fund IV, L.P. beneficially owns 1,960,774 shares, representing 3.6% of Eikon Therapeutics' common stock.
• Foresite Capital Fund V, L.P. beneficially owns 1,353,168 shares, representing 2.5% of Eikon Therapeutics' common stock.
• Foresite Capital Opportunity Fund V, L.P. beneficially owns 425,852 shares, representing 0.8% of Eikon Therapeutics' common stock.
• Foresite Capital VI-A, LLC beneficially owns 408,725 shares, representing 0.8% of Eikon Therapeutics' common stock.
• James B. Tananbaum, as managing member of the general partners/managing members of the Foresite entities, is deemed to beneficially own an aggregate of 4,148,519 shares, representing 7.7% of Eikon Therapeutics' common stock.
• The beneficial ownership percentages are calculated based on 53,984,337 shares of Common Stock outstanding as of February 4, 2026.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor like Foresite Capital increasing or maintaining a substantial stake can be interpreted as a vote of confidence in the company's long-term prospects.

Positives

• Significant institutional investment from Foresite Capital, a prominent healthcare and life sciences investor, signals confidence in Eikon Therapeutics.
• James B. Tananbaum's aggregate beneficial ownership of 7.7% demonstrates a substantial commitment from a key figure within Foresite Capital.

Risks

• The filing does not detail specific risks related to Eikon Therapeutics' operations or financial performance, as it is a beneficial ownership disclosure.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Eikon Therapeutics' future performance or Foresite Capital's investment strategy beyond the current holdings.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes by investment funds. Foresite Capital is known for its focus on healthcare and life sciences, suggesting Eikon Therapeutics aligns with their investment thesis in the biotechnology sector. Such disclosures can sometimes precede further engagement or indicate a long-term investment horizon.

Comparison to Industry Standards

• Foresite Capital's aggregate 7.7% stake in Eikon Therapeutics is a notable position for an institutional investor, often considered a significant vote of confidence in a company, particularly in the biotech space where early-stage investments are common.
• Compared to typical passive institutional holdings, a 7.7% stake by a specialized fund like Foresite Capital suggests a more concentrated and potentially strategic investment, aligning with their venture capital and growth equity approach in life sciences.

Related Party Transactions

• Under certain circumstances, the partners or members of Foresite Capital's various funds (FCF IV, FCF V, FCF Opp V, FC VI-A, FCM VI-A, FCM IV, FCM V, and FCM Opp V) may be deemed to have the right to receive dividends or proceeds from the sale of Eikon Therapeutics shares directly or indirectly owned by these entities.

Stakeholder Impact

• Shareholders may view the significant institutional ownership by Foresite Capital as a positive indicator of Eikon Therapeutics' value and potential, potentially influencing investor sentiment and stock price.

Key Dates

Recommendation

The disclosure of a significant institutional stake by Foresite Capital is generally a positive signal, indicating confidence from a sophisticated investor. However, a Schedule 13G filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'strong buy' recommendation. It primarily confirms existing or slightly adjusted ownership. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions while acknowledging the positive institutional interest.

Keywords

Eikon Therapeutics, Foresite Capital, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Biotechnology, Healthcare Investment